The coronavirus could help pharma reset its reputation in Washington

  • STAT | by: Nicholas Florko |
  • 03/03/2020 12:00 AM
BIO says it has more than 20 companies pursuing coronavirus vaccines, therapeutics, or other products. Members like Moderna Therapeutics and Inovio are in the early stages of developing their own vaccines.

Drug industry critics, however, are unlikely to be impressed by pharma’s goodwill. Already, Democrats are insisting that drug makers should make any coronavirus treatment affordable. And the advocacy group Public Citizen has already criticized the drug industry for neglecting coronaviruses and vaccines more generally for more lucrative projects.

It’s also still too early to tell too whether Trump will be wooed by drug makers’ vaccine efforts and abandon his tough talk toward pharma, but drug industry defenders say it’s worth a shot.

“In a political season, telling politicians to put down really potent but incorrect and dangerous talking points may or may not be a fantasy,” said Peter Pitts, president of Center for Medicine in the Public Interest, which receives drug industry funding. “But it’s a battle worth fighting.”

 
Sign Up for Our Email Newsletter

RECENT NEWS

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

How proactive FDA policies can help strengthen the American pharmaceutical supply chain of essential medicines, create jo...  Read more

The Empty Price Tag

The Empty Price Tag

Why Hospital Price Transparency Has Fallen Short & How Congress Can Make It Right...  Read more

We Can Fight Fraud Without Threatening Access to Care

We Can Fight Fraud Without Threatening Access to Care

When Washington fails to police its own programs, it’s hardworking Americans that pay the price. ...  Read more

DRUGWONKS BLOG